Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marco Torri is active.

Publication


Featured researches published by Marco Torri.


Journal of Medicinal Chemistry | 2008

Novel Analogues of Istaroxime, a Potent Inhibitor of Na+,K+-ATPase: Synthesis and Structure−Activity Relationship†

Mauro Gobbini; Silvia Armaroli; Leonardo Banfi; Alessandra Benicchio; Giulio Carzana; Giorgio Fedrizzi; Patrizia Ferrari; Giuseppe Giacalone; Michele Giubileo; Giuseppe Marazzi; Rosella Micheletti; Barbara Moro; Marco Pozzi; Piero Enrico Scotti; Marco Torri; Alberto Cerri

We report the synthesis and biological properties of novel inhibitors of the Na(+),K(+)-ATPase as positive inotropic compounds. Following our previously described model from which Istaroxime was generated, the 5alpha,14alpha-androstane skeleton was used as a scaffold to study the space around the basic chain of our lead compound. Some compounds demonstrated higher potencies than Istaroxime on the receptor and the (E)-3-[(R)-3-pyrrolidinyl]oxime derivative, 15, was the most potent; as further confirmation of our model, the E isomers of the oxime are more potent than the Z form. The compounds tested in the guinea pig model induced positive inotropic effects, which are correlated to the in vitro inhibitory potency on the Na(+),K(+)-ATPase. The finding that all tested compounds resulted less proarrhythmogenic than digoxin, a currently clinically used positive inotropic agent, suggests that this could be a feature of the 3-aminoalkyloxime derivative class of 5alpha,14alpha-androstane.


Journal of Chromatography A | 2011

Identification of impurities in artemisinin, their behavior in high performance liquid chromatography and implications for the quality of derived anti-malarial drugs.

Rodger W. Stringham; Michael Pennell; Walter Cabri; Giulio Carzana; Fabrizio Giorgi; Silvana Lalli; Giuseppe Marazzi; Marco Torri

Previous work [1] on the HPLC analysis of artemisinin tentatively identified the two impurities present above trace levels. This identification was based on LC-MS results and NMR of impurities isolated from artemisinin. In this work the impurities have been synthesized allowing verification of their identity by LC-MS. It is found that the previously suggested elution order is incorrect. A determination of relative response factors strongly impacts suggested limits on impurity levels and explains the erroneous peak assignment. The fates of the identified impurities are explored in the transformation of artemisinin to its derivative active pharmaceutical ingredients. A survey of a wide variety of artemisinin samples isolated from different geographical regions, different growing seasons, different plant backgrounds and using different extraction and purification approaches showed that artemisinin has sufficient purity for its intended use as a raw material for anti-malarial drug products.


Bioorganic & Medicinal Chemistry | 2010

Novel analogues of Istaroxime, a potent inhibitor of Na+,K+-ATPase: Synthesis, structure–activity relationship and 3D-quantitative structure–activity relationship of derivatives at position 6 on the androstane scaffold

Mauro Gobbini; Silvia Armaroli; Leonardo Banfi; Alessandra Benicchio; Giulio Carzana; Patrizia Ferrari; Giuseppe Giacalone; Giuseppe Marazzi; Barbara Moro; Simona Sputore; Marco Torri; Maria Pia Zappavigna; Alberto Cerri

We report the synthesis and biological properties of novel analogues of Istaroxime acting as positive inotropic compounds through the inhibition of the Na(+),K(+)-ATPase. We explored the chemical space around the position 6 of the steroidal scaffold by changing the functional groups at that position and maintaining a basic oximic chain in position 3. Some compounds showed inhibitory potencies of the Na(+),K(+)-ATPase higher than Istaroxime and many of the compounds tested in vivo were safer than digoxin, the classic digitalis compound currently used for the treatment of congestive heart failure as inotropic agent. The 3D-QSAR analyses using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) methods have been successfully applied to a set of 63 androstane derivatives as Na(+),K(+)-ATPase inhibitors. The contour plots provide many useful insights into relationships between structural features and inhibitory potency.


Bioorganic & Medicinal Chemistry Letters | 1997

Digitalis-like compounds: Synthesis and biological evaluation of 3β-(aminoalkylthio) derivatives

Mauro Gobbini; Alessandra Benicchio; Gloria Padoani; Marco Torri; Piero Melloni

Abstract The synthesis and the binding affinities to the digitalis receptor on the Na+,K+-ATPase of a series of 3β-(aminoalkylthio) digitalis derivatives are described. In most cases these derivatives showed a higher binding affinity than that of the corresponding 3β-hydroxy and 3β-mercapto parent compoubds.


Steroids | 1996

Digitalis-like compounds: Synthesis and biological evaluation of seco-D and D-homo derivatives

Mauro Gobbini; Alessandra Benicchio; Giuseppe Marazzi; Gloria Padoani; Marco Torri; Piero Melloni

The synthesis of seco-D and D-homo digitalis derivatives, from the carda-14,20(22)-dienolide 1, is described. Selective ozonolysis gave the seco-D 14-ketoaldehyde 2a. Modification of the two carbonyl groups and of the alpha, beta-unsaturated lactone ring of the seco-D 14-ketoaldehyde 2a allowed preparation of derivatives with a broad range of binding affinity to the Na+, K(+)-ATPase receptor. Some of the seco-D derivatives (10, 11b, and 13b) showed a binding affinity similar to that of digitoxigenin, demonstrating that the D-ring is not essential for recognition by the digitalis receptor. In the class of D-homo derivatives the highest binding value, about 15 times lower than that of digitoxigenin, was that of the C/D cis compound 29b; the C/D trans analog 28b showed a 7-fold decrease in binding affinity, indicating that the C/D configuration plays an important role in D-homo derivatives as in the classical digitalis compounds.


Synthetic Communications | 1997

An Expeditious Route to 3β,14β-Dihydroxy-5β-androstane-17β-carboxaldehyde

Mauro Gobbini; Marco Torri

Abstract An efficient and practical synthesis of 3β,14β-dihydroxy-5β-androstane-17β-carboxaldehyde is described. The key oxidative cleavage of the unsaturated lactone of 3-acetyldigitoxigenin 1 utilises RuO4 as catalytic and NaIO4 as stoichiometric oxidants.


Journal of Medicinal Chemistry | 1997

17β-(3-Furyl)-5β-androstane-3β,14β,17α-triol (PST 2238). A Very Potent Antihypertensive Agent with a Novel Mechanism of Action

Luisa Quadri; Giuseppe Bianchi; Alberto Cerri; Giorgio Fedrizzi; Patrizia Ferrari; Mauro Gobbini; Piero Melloni; Simona Sputore; Marco Torri


Journal of Medicinal Chemistry | 2003

Structure-Based Design and Synthesis of Novel Potent Na+,K+-ATPase Inhibitors Derived from a 5α,14α-Androstane Scaffold as Positive Inotropic Compounds

Sergio De Munari; Alberto Cerri; Mauro Gobbini; Nicoletta Almirante; Leonardo Banfi; Giulio Carzana; Patrizia Ferrari; Giuseppe Marazzi; Rosella Micheletti; Antonio Schiavone; Simona Sputore; Marco Torri; Maria Pia Zappavigna; Piero Melloni


Journal of Medicinal Chemistry | 2001

17α-O-(Aminoalkyl)oxime derivatives of 3β, 14β-dihydroxy-5β-androstane and 3β-hydroxy-14-oxoseco-d-5β-androstane as inhibitors of Na+, K+-ATPase at the digitalis receptor

Mauro Gobbini; Paolo Barassi; Alberto Cerri; Sergio De Munari; Giorgio Fedrizzi; Marco Santagostino; Antonio Schiavone; Marco Torri; Piero Melloni


Archive | 1996

Seco-D steroids active on the cardiovascular system and pharmaceutical compositions containing same

Mauro Gobbini; Patrizia Ferrari; Piero Melloni; Marco Torri

Collaboration


Dive into the Marco Torri's collaboration.

Researchain Logo
Decentralizing Knowledge